Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting
Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis
Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV). Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…Abstract Number: 2197 • 2018 ACR/ARHP Annual Meeting
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Background/Purpose: Giant cell arteritis (GCA) and polymialgia rheumatica (PMR) are overlapping inflammatory diseases. Large Vessel Vasculitis (LVV) is frequently present in any of the two…Abstract Number: 2777 • 2018 ACR/ARHP Annual Meeting
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large vessels requiring long-term treatment with glucocorticoids. The immunopathology is characterized by vessel infiltrating innate…Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting
Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…Abstract Number: 2843 • 2018 ACR/ARHP Annual Meeting
Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
Background/Purpose: LEF could be the favourable DMARD for PMR/GCA due to inhibitory activity on dendritic cells and IL-6. Previous case series have shown efficacy of…Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study
Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…Abstract Number: 2905 • 2018 ACR/ARHP Annual Meeting
Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
Background/Purpose: EULAR recommendations suggest diagnostic imaging in all GCA suspects. Vascular ultrasound (US) is cheap, readily available and the recommended first line examination in cranial…Abstract Number: 2747 • 2018 ACR/ARHP Annual Meeting
Leflunomide and Methotrexate in Treatment of Giant Cell Arteritis: Comparison of Efficacy, Safety and Drug Survival
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are used as adjunct immunosuppressants and corticosteroid sparing agents in treatment of Giant Cell Arteritis (GCA), but the efficacy…Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…Abstract Number: 2748 • 2018 ACR/ARHP Annual Meeting
Giant Cell Arteritis in Treatment with Tocilizumab. Evolution of Vascular FDG Uptake on PET/CT
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in…Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…Abstract Number: 2753 • 2018 ACR/ARHP Annual Meeting
Extension of Extracranial Vessel Involvement in Patients with Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis with a predisposition for the cranial branches of the external carotid artery. However, aorta and…
- « Previous Page
- 1
- …
- 17
- 18
- 19
- 20
- 21
- …
- 28
- Next Page »